B cells play a central role in the pathogenesis of multiple sclerosis (MS): they are involved in
the activation of pro-inflammatory T cells, secretion of pro-inflammatory cytokines and …

B cells play a central role in the pathogenesis in multiple sclerosis (MS), being involved in
the activation of proinflammatory T cells, secretion of proinflammatory cytokines, and …

Ocrelizumab (Ocrevus®) is an intravenously administered, humanized anti-CD20
monoclonal antibody approved for the treatment of adults with relapsing forms of multiple …

Ocrelizumab (Ocrevus®) is a humanized anti-CD20 monoclonal antibody approved for the
treatment of adults with relapsing multiple sclerosis (RMS) or primary progressive multiple …

Conclusions Ocrelizumab is the first drug that has been shown to be able to significantly
slow disability progression at 12 and 24 weeks in patients with PPMS. It is also effective in …

Background B cells influence the pathogenesis of multiple sclerosis. Ocrelizumab is a
humanized monoclonal antibody that selectively depletes CD20+ B cells. Methods In two …

Across its clinical development program, ocrelizumab demonstrated efficacy in improving
clinical outcomes in multiple sclerosis, including annualized relapse rates and confirmed …

Objective To assess over 3 years of follow-up the effects of maintaining or switching to
ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open …

Objective Pivotal trial have shown that patients with multiple sclerosis (MS) receiving
ocrelizumab had better outcomes. However, data on ocrelizumab in clinical practice are …

Background B lymphocytes are implicated in the pathogenesis of multiple sclerosis. We
aimed to assess efficacy and safety of two dose regimens of the humanised anti-CD20 …